Senores Pharmaceuticals Peer Comparison

NSE: SENORES | BSE: 544319

₹1,355.20

₹10.90 (0.81%)

As on 25-Sep-2026IST

Market cap

₹6,245 Cr

Revenue (TTM)

₹692 Cr

P/E Ratio

49.4

P/B Ratio

6.5

Div. Yield

0 %

Edit

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	6,245	36,902	28,103	16,761	15,213
Revenue (₹ Cr)	692	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	130.82	1,018.97	497.77	603.02	270.18
Net Margin (%)	18.13	10.47	20.72	22.63	23.29
RoE (%)	14.46	21.30	28.49	19.61	14.45
Price to Earnings	49.42	36.49	56.46	27.79	55.25
Price-To-Book	6.48	7.05	13.90	4.81	7.34

Income Statement (₹ Cr)

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	691.72	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	721.39	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	486.96	7,739.53	1,608.91	1,753.71	720.01
EBITDA	204.76	1,943.92	762.90	836.69	388.38
Depreciation	35.19	425.10	98.11	78.88	74.78
EBIT	169.57	1,518.82	664.79	757.81	313.60
Interest	27.15	148.45	26.33	5.43	0.26
Other Income	29.67	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	172.09	1,389.91	669.26	800.55	361.56
Provision for Tax	41.27	370.94	171.48	197.53	91.39
Profit after Tax	130.82	1,018.97	497.77	603.02	270.18

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	933.60	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	-4.45	-7.58	0.00	0.00	2.51
Non-Current Liabilities	215.27	723.57	345.47	142.73	50.51
Current Liabilities	424.00	3,912.24	710.20	508.04	169.08
Total Liabilities	1,603.81	9,514.48	2,930.14	4,157.10	2,231.79

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	763.06	3,392.16	1,290.62	1,321.38	957.22
Current Assets	812.43	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	1,603.81	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	327.09	1,204.08	196.61	0.00	0.00
Net Current Assets	388.43	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	24.43	258.92	13.18	4.82	3.76

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	62.05	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-120.56	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-1.33	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-59.84	93.92	-56.08	-69.08	11.28

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	15.66	25.25	27.50	24.61	18.04
ROE (%)	14.46	21.30	28.49	19.61	14.45
ROA (%)	9.24	11.42	19.48	16.31	12.66
EBIT Margin (%)	24.51	15.68	28.03	29.25	28.29
Net Margin (%)	18.13	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	53.57	18.36	78.33	7.93	-6.72
EBIT Growth (%)	117.98	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	90.67	32.39	182.61	21.66	-24.38
EPS Growth (%)	87.05	36.68	277.72	25.42	-21.99
Book Value Growth (%)	18.71	11.36	22.95	18.43	11.27

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	49.42	35.74	56.46	26.91	54.76
Price / Book Value	6.48	7.05	13.90	4.81	7.34
Dividend Yield (%)	0.00	0.19	0.16	0.37	0.52
EV/EBITDA	31.32	19.53	36.63	19.10	38.10
Market Cap (₹ Cr)	3,490.16	30,257.56	15,412.11	11,956.86	10,627.92

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.21	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.03	0.16	--	--	--
Current Ratio	1.92	1.43	2.09	5.21	7.39
Quick Ratio	1.71	0.82	1.37	3.85	5.46
Interest Coverage	7.34	10.36	26.41	148.49	1,386.30

	Senores Pharmaceuticals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	46.96	26.46	22.82	41.42	41.52
Asset Turnover	0.49	1.09	0.93	0.70	0.52
Receivable days	129.44	88.68	77.32	144.58	169.86
Inventory Days	42.09	84.11	80.83	96.67	97.92
Payable days	218.97	176.65	125.94	135.45	159.68
Cash Conversion Cycle	-47.43	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.